IRONWOOD PHARMACEUTICALS, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $737.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Equity
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2025-11-10
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-06-30 was $121.00K.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-03-31 was $616.00K.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $737.00K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|
| 2024-12-31 | $737.00K 10-K · filed 2025-03-31 | ||
| 2024-06-30 | $121.00K 10-Q · filed 2025-11-10 | $737.00K derived: sum of 2 quarters · filed 2025-11-10 | |
| 2024-03-31 | $616.00K 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |